Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody
Circulating influenza viruses evade neutralization in their human hosts by acquiring escape mutations at epitopes of prevalent antibodies. A goal for next-generation influenza vaccines is to reduce escape likelihood by selectively eliciting antibodies recognizing conserved surfaces on the viral hema...
Saved in:
| Published in: | Proceedings of the National Academy of Sciences - PNAS Vol. 115; no. 1; p. 168 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
02.01.2018
|
| Subjects: | |
| ISSN: | 1091-6490, 1091-6490 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Circulating influenza viruses evade neutralization in their human hosts by acquiring escape mutations at epitopes of prevalent antibodies. A goal for next-generation influenza vaccines is to reduce escape likelihood by selectively eliciting antibodies recognizing conserved surfaces on the viral hemagglutinin (HA). The receptor-binding site (RBS) on the HA "head" and a region near the fusion peptide on the HA "stem" are two such sites. We describe here a human antibody clonal lineage, designated CL6649, members of which bind a third conserved site ("lateral patch") on the side of the H1-subtype, HA head. A crystal structure of HA with bound Fab6649 shows the conserved antibody footprint. The site was invariant in isolates from 1977 (seasonal) to 2012 (pdm2009); antibodies in CL6649 recognize HAs from the entire period. In 2013, human H1 viruses acquired mutations in this epitope that were retained in subsequent seasons, prompting modification of the H1 vaccine component in 2017. The mutations inhibit Fab6649 binding. We infer from the rapid spread of these mutations in circulating H1 influenza viruses that the previously subdominant, conserved lateral patch had become immunodominant for individuals with B-cell memory imprinted by earlier H1 exposure. We suggest that introduction of the pdm2009 H1 virus, to which most of the broadly prevalent, neutralizing antibodies did not bind, conferred a selective advantage in the immune systems of infected hosts to recall of memory B cells that recognized the lateral patch, the principal exposed epitope that did not change when pdm2009 displaced previous seasonal H1 viruses. |
|---|---|
| AbstractList | Circulating influenza viruses evade neutralization in their human hosts by acquiring escape mutations at epitopes of prevalent antibodies. A goal for next-generation influenza vaccines is to reduce escape likelihood by selectively eliciting antibodies recognizing conserved surfaces on the viral hemagglutinin (HA). The receptor-binding site (RBS) on the HA "head" and a region near the fusion peptide on the HA "stem" are two such sites. We describe here a human antibody clonal lineage, designated CL6649, members of which bind a third conserved site ("lateral patch") on the side of the H1-subtype, HA head. A crystal structure of HA with bound Fab6649 shows the conserved antibody footprint. The site was invariant in isolates from 1977 (seasonal) to 2012 (pdm2009); antibodies in CL6649 recognize HAs from the entire period. In 2013, human H1 viruses acquired mutations in this epitope that were retained in subsequent seasons, prompting modification of the H1 vaccine component in 2017. The mutations inhibit Fab6649 binding. We infer from the rapid spread of these mutations in circulating H1 influenza viruses that the previously subdominant, conserved lateral patch had become immunodominant for individuals with B-cell memory imprinted by earlier H1 exposure. We suggest that introduction of the pdm2009 H1 virus, to which most of the broadly prevalent, neutralizing antibodies did not bind, conferred a selective advantage in the immune systems of infected hosts to recall of memory B cells that recognized the lateral patch, the principal exposed epitope that did not change when pdm2009 displaced previous seasonal H1 viruses.Circulating influenza viruses evade neutralization in their human hosts by acquiring escape mutations at epitopes of prevalent antibodies. A goal for next-generation influenza vaccines is to reduce escape likelihood by selectively eliciting antibodies recognizing conserved surfaces on the viral hemagglutinin (HA). The receptor-binding site (RBS) on the HA "head" and a region near the fusion peptide on the HA "stem" are two such sites. We describe here a human antibody clonal lineage, designated CL6649, members of which bind a third conserved site ("lateral patch") on the side of the H1-subtype, HA head. A crystal structure of HA with bound Fab6649 shows the conserved antibody footprint. The site was invariant in isolates from 1977 (seasonal) to 2012 (pdm2009); antibodies in CL6649 recognize HAs from the entire period. In 2013, human H1 viruses acquired mutations in this epitope that were retained in subsequent seasons, prompting modification of the H1 vaccine component in 2017. The mutations inhibit Fab6649 binding. We infer from the rapid spread of these mutations in circulating H1 influenza viruses that the previously subdominant, conserved lateral patch had become immunodominant for individuals with B-cell memory imprinted by earlier H1 exposure. We suggest that introduction of the pdm2009 H1 virus, to which most of the broadly prevalent, neutralizing antibodies did not bind, conferred a selective advantage in the immune systems of infected hosts to recall of memory B cells that recognized the lateral patch, the principal exposed epitope that did not change when pdm2009 displaced previous seasonal H1 viruses. Circulating influenza viruses evade neutralization in their human hosts by acquiring escape mutations at epitopes of prevalent antibodies. A goal for next-generation influenza vaccines is to reduce escape likelihood by selectively eliciting antibodies recognizing conserved surfaces on the viral hemagglutinin (HA). The receptor-binding site (RBS) on the HA "head" and a region near the fusion peptide on the HA "stem" are two such sites. We describe here a human antibody clonal lineage, designated CL6649, members of which bind a third conserved site ("lateral patch") on the side of the H1-subtype, HA head. A crystal structure of HA with bound Fab6649 shows the conserved antibody footprint. The site was invariant in isolates from 1977 (seasonal) to 2012 (pdm2009); antibodies in CL6649 recognize HAs from the entire period. In 2013, human H1 viruses acquired mutations in this epitope that were retained in subsequent seasons, prompting modification of the H1 vaccine component in 2017. The mutations inhibit Fab6649 binding. We infer from the rapid spread of these mutations in circulating H1 influenza viruses that the previously subdominant, conserved lateral patch had become immunodominant for individuals with B-cell memory imprinted by earlier H1 exposure. We suggest that introduction of the pdm2009 H1 virus, to which most of the broadly prevalent, neutralizing antibodies did not bind, conferred a selective advantage in the immune systems of infected hosts to recall of memory B cells that recognized the lateral patch, the principal exposed epitope that did not change when pdm2009 displaced previous seasonal H1 viruses. |
| Author | Schmidt, Aaron G Harrison, Stephen C Bajic, Goran Ferdman, Jack Suphaphiphat, Pirada Settembre, Ethan C Moody, M Anthony Raymond, Donald D |
| Author_xml | – sequence: 1 givenname: Donald D surname: Raymond fullname: Raymond, Donald D organization: Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115 – sequence: 2 givenname: Goran surname: Bajic fullname: Bajic, Goran organization: Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115 – sequence: 3 givenname: Jack surname: Ferdman fullname: Ferdman, Jack organization: Seqirus, Cambridge, MA 02139 – sequence: 4 givenname: Pirada surname: Suphaphiphat fullname: Suphaphiphat, Pirada organization: Seqirus, Cambridge, MA 02139 – sequence: 5 givenname: Ethan C surname: Settembre fullname: Settembre, Ethan C organization: Seqirus, Cambridge, MA 02139 – sequence: 6 givenname: M Anthony surname: Moody fullname: Moody, M Anthony organization: Duke Human Vaccine Institute, Duke University Medical School, Durham, NC 27710 – sequence: 7 givenname: Aaron G surname: Schmidt fullname: Schmidt, Aaron G organization: Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115 – sequence: 8 givenname: Stephen C surname: Harrison fullname: Harrison, Stephen C email: harrison@crystal.harvard.edu organization: Howard Hughes Medical Institute, Boston, MA 02115 |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29255041$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUE1LxDAUDLLifujZm-TopWtemjTpURZXhQUvepTymqZrpE1r0yysv96CK3h6b4aZx5tZkpnvvCXkGtgamErveo9hDQqkUAAgz8gCWA5JJnI2-7fPyTKET8ZYLjW7IHOecymZgAV533Q-2OFgK2p7N3a9pZ2nztdNtP4bk4MbYqAftsX9vomj885PCCta2dr5yVUeKdIDGjOhxPkqmolEP7qyq46X5LzGJtir01yRt-3D6-Yp2b08Pm_ud4mRio-JqLm2eSZ5rZRKa8SUC2349LmWJRhQAkWphZQGQXKT6xqAaZlN-VJUsuQrcvt7tx-6r2jDWLQuGNs06G0XQwG50opnnLFJenOSxrK1VdEPrsXhWPxVwn8At6Rk7w |
| CitedBy_id | crossref_primary_10_1016_j_vetmic_2019_108425 crossref_primary_10_3390_v10040197 crossref_primary_10_3390_v13040546 crossref_primary_10_1155_2024_5691673 crossref_primary_10_1038_s41467_024_48758_4 crossref_primary_10_1080_22221751_2025_2494702 crossref_primary_10_3390_v11050405 crossref_primary_10_3390_vaccines9060657 crossref_primary_10_1016_j_crmeth_2023_100566 crossref_primary_10_1093_infdis_jiz044 crossref_primary_10_3389_fimmu_2022_816634 crossref_primary_10_7554_eLife_83628 crossref_primary_10_1038_s41467_023_43339_3 crossref_primary_10_3390_vaccines9020075 crossref_primary_10_1038_s41467_024_55193_y crossref_primary_10_1007_s00705_024_06210_4 crossref_primary_10_1038_s41541_021_00417_1 crossref_primary_10_3390_vaccines11030593 crossref_primary_10_1038_s41590_018_0305_x crossref_primary_10_1016_j_coi_2020_03_013 crossref_primary_10_1111_imr_13431 crossref_primary_10_1016_j_immuni_2019_06_024 crossref_primary_10_1038_s41467_022_32926_5 crossref_primary_10_1016_j_coviro_2022_101207 crossref_primary_10_1186_s12985_020_01458_z crossref_primary_10_1038_s41586_021_04356_8 crossref_primary_10_3390_antib14010004 crossref_primary_10_1016_j_imbio_2022_152279 crossref_primary_10_1038_s41577_020_00479_7 crossref_primary_10_1093_ofid_ofaf440 crossref_primary_10_1128_JVI_00052_20 crossref_primary_10_1016_j_drudis_2024_104125 crossref_primary_10_3389_fcimb_2019_00344 crossref_primary_10_3390_vaccines8030382 crossref_primary_10_1016_j_immuni_2019_09_001 crossref_primary_10_1093_infdis_jiy441 crossref_primary_10_1128_jvi_01646_22 crossref_primary_10_1016_j_antiviral_2023_105785 crossref_primary_10_1103_PhysRevE_103_052408 crossref_primary_10_1016_j_celrep_2024_114171 crossref_primary_10_1186_s12985_022_01745_x crossref_primary_10_3389_fimmu_2022_1029167 crossref_primary_10_3390_vaccines8030424 crossref_primary_10_1371_journal_pbio_3000164 crossref_primary_10_1038_s41541_021_00403_7 crossref_primary_10_1093_infdis_jiy711 crossref_primary_10_1074_jbc_RA118_007008 crossref_primary_10_1038_s41598_023_27965_x crossref_primary_10_1016_j_cell_2019_03_048 crossref_primary_10_3389_fcimb_2022_990875 crossref_primary_10_1016_j_cels_2020_09_005 crossref_primary_10_1016_j_micpath_2021_105095 crossref_primary_10_1016_j_virusres_2024_199402 crossref_primary_10_1016_j_vaccine_2018_06_054 crossref_primary_10_1038_s41573_019_0056_x crossref_primary_10_1038_s41467_025_59294_0 crossref_primary_10_3390_v11020177 crossref_primary_10_4049_jimmunol_2101171 crossref_primary_10_1371_journal_pone_0239112 crossref_primary_10_1002_smtd_202101516 crossref_primary_10_1093_ve_veab020 crossref_primary_10_1371_journal_pbio_2004974 crossref_primary_10_1007_s11684_020_0764_y crossref_primary_10_3390_microorganisms8111745 crossref_primary_10_1016_j_immuni_2025_02_006 crossref_primary_10_1002_cti2_1345 crossref_primary_10_1002_jcb_29017 crossref_primary_10_1016_j_immuni_2020_10_005 crossref_primary_10_1126_sciadv_adu9140 crossref_primary_10_3389_fimmu_2019_02997 crossref_primary_10_1126_sciimmunol_abn5311 crossref_primary_10_1126_scitranslmed_abg4535 crossref_primary_10_1128_JVI_00859_18 crossref_primary_10_3390_v15020347 crossref_primary_10_1038_s41598_024_74438_w crossref_primary_10_1016_j_str_2024_05_001 crossref_primary_10_1080_07391102_2023_2292293 crossref_primary_10_1038_s41598_021_84891_6 crossref_primary_10_1093_intimm_dxaa028 crossref_primary_10_1073_pnas_1919329117 crossref_primary_10_3390_v13060965 crossref_primary_10_1093_ve_veaf014 crossref_primary_10_1371_journal_pbio_3000139 crossref_primary_10_3389_fimmu_2019_00440 crossref_primary_10_3389_fimmu_2020_607333 crossref_primary_10_3390_vaccines9020125 crossref_primary_10_1016_j_csbj_2019_03_009 crossref_primary_10_1016_j_coi_2018_05_010 crossref_primary_10_1038_s41467_018_06228_8 crossref_primary_10_1099_jgv_0_001251 crossref_primary_10_1371_journal_pone_0280627 crossref_primary_10_3390_vaccines6030035 crossref_primary_10_3390_v12091053 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 the Author(s). Published by PNAS. |
| Copyright_xml | – notice: Copyright © 2017 the Author(s). Published by PNAS. |
| DBID | NPM 7X8 |
| DOI | 10.1073/pnas.1715471115 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 1091-6490 |
| ExternalDocumentID | 29255041 |
| Genre | Journal Article |
| GroupedDBID | --- -DZ -~X .55 0R~ 123 29P 2AX 2FS 2WC 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACNCT ACPRK ADULT AENEX AEUPB AEXZC AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM BKOMP CS3 D0L DCCCD DIK DOOOF DU5 E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KQ8 L7B LU7 N9A NPM N~3 O9- OK1 PNE PQQKQ R.V RHF RHI RNA RNS RPM RXW SA0 SJN TAE TN5 UKR VQA W8F WH7 WOQ WOW X7M XSW Y6R YBH YIF YIN YKV YSK ZCA ~02 ~KM 7X8 ADQXQ |
| ID | FETCH-LOGICAL-c572t-4f28e9652f7773faa3248c264985b1c174a4b8455ca152c98f1108561093a75b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 114 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000419128700046&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1091-6490 |
| IngestDate | Thu Oct 02 03:02:15 EDT 2025 Wed Feb 19 02:42:31 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | B-cell memory influenza vaccine hemagglutinin affinity maturation |
| Language | English |
| License | Copyright © 2017 the Author(s). Published by PNAS. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c572t-4f28e9652f7773faa3248c264985b1c174a4b8455ca152c98f1108561093a75b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.pnas.org/doi/10.1073/pnas.1715471115 |
| PMID | 29255041 |
| PQID | 1978726200 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1978726200 pubmed_primary_29255041 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-02 |
| PublicationDateYYYYMMDD | 2018-01-02 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
| PublicationTitleAlternate | Proc Natl Acad Sci U S A |
| PublicationYear | 2018 |
| SSID | ssj0009580 |
| Score | 2.5646946 |
| Snippet | Circulating influenza viruses evade neutralization in their human hosts by acquiring escape mutations at epitopes of prevalent antibodies. A goal for... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 168 |
| Title | Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29255041 https://www.proquest.com/docview/1978726200 |
| Volume | 115 |
| WOSCitedRecordID | wos000419128700046&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3PS8MwFA7qPHhR58_5iwge9BC3Nk2TnETE4UHHDgq7yEjSZPTS1nUbzL_el7ZDL4LgJdBDoCTvJd_33sv3ELqK4iBhxsUEoL8P3QBnVdZpokNGLaUyDkylrv_MBwMxGslhE3Arm7LK1ZlYHdRJbnyMvBsA3eFePb13V3wQ3zXKZ1ebFhrrqEUByviSLj4SP0R3Ra1GIAMSR7K3kvbhtFtkqrwNOAAIDt7OfseX1T3T3_nvH-6i7QZh4vvaJNpozWZ7qN34cImvG6Hpm3307rt1-orHBNsCPLuwOM9wWrct-VRkkU7nJfaqrpOJN9AszeBLJTixDsBpgvUSK7xQxifnCZB7MJMEw1alOk-WB-it__j68ESadgvEMB7OSORCYWXMQsc5p04pwFrCAGCSgunAAHVRkRYRY0bBpW-kcP4JgcdfkirOdHiINrI8s8e-XsppYVSslbaRZVyryFHmAyY05EDyOuhytYRjMGefo1CZzefl-HsRO-io3odxUetujEMJ_KcXBSd_mH2KtgDaiCpYEp6hlgNntudo0yxmaTm9qOwExsHw5QtHfsb9 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Conserved+epitope+on+influenza-virus+hemagglutinin+head+defined+by+a+vaccine-induced+antibody&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Raymond%2C+Donald+D&rft.au=Bajic%2C+Goran&rft.au=Ferdman%2C+Jack&rft.au=Suphaphiphat%2C+Pirada&rft.date=2018-01-02&rft.eissn=1091-6490&rft_id=info:doi/10.1073%2Fpnas.1715471115&rft_id=info%3Apmid%2F29255041&rft_id=info%3Apmid%2F29255041&rft.externalDocID=29255041 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1091-6490&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1091-6490&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1091-6490&client=summon |